» Articles » PMID: 1148621

Adrenergic and Cholinergic Receptors in the Human Prostate, Prostatic Capsule and Bladder Neck

Overview
Journal Br J Urol
Specialty Urology
Date 1975 Apr 1
PMID 1148621
Citations 70
Authors
Affiliations
Soon will be listed here.
Abstract

The adrenergic and cholinergic receptors of the human prostatic capsule, prostatic "adenoma", and bladder neck, were investigated by the in-vitro isometric technique. The prostatic capsule was found to be very rich in both alpha-adrenergic receptors and cholinergic receptors. The prostatic adenoma was moderately rich in alpha-adrenergic receptors, but cholinergic receptors were absent. Beta-adrenergic receptors were absent in the prostatic adenoma, and there was an equivocal response in less than half the specimens of the prostatic capsule. An attempt was made to distinguish between the trigonal component at the posterior bladder neck, and the true bladder neck muscle both posteriorly and antero-laterally. The results indicat that the "posterior bladder neck" seen at operation is predominantly trigonal muscle, and is poor in cholinergic receptors. The adrenergic response is variable in the true bladder neck muscle, but is present and strong in the trigonal muscle. This response is characteristically gradual in its development. In view of the findings in this investigation, it is suggested that certain instances of acute retention of urine in prostatic patients are due to over-stimulation of the alpha-adrenergic receptors, particularly those in the prostatic capsule. Similarly, the accepted clinical contraindication to the use of cholinergic drugs for retention in the prostatic patient is supported by the distribution of the cholinergic receptors in the tissues examined.

Citing Articles

Periprostatic adipose tissue inhibits tumor progression by secreting apoptotic factors: A natural barrier induced by the immune response during the early stages of prostate cancer.

Shao I, Chang T, Chang Y, Hsieh Y, Sheng T, Wang L Oncol Lett. 2024; 28(4):485.

PMID: 39170882 PMC: 11338243. DOI: 10.3892/ol.2024.14617.


Response Surface Methodology (RSM) approach to formulate and optimize the bilayer combination tablet of Tamsulosin and Finasteride.

Akhtar M, Zaman M, Siddiqi A, Ali H, Khan R, Alvi M Saudi Pharm J. 2024; 32(3):101957.

PMID: 38313822 PMC: 10837631. DOI: 10.1016/j.jsps.2024.101957.


New therapeutic targets to prevent benign prostatic enlargement and symptomatic progression to benign prostatic obstruction-ICI-RS 2023.

Kanai A, Chakrabarty B, Winder M, Hashim H, Wein A, Abrams P Neurourol Urodyn. 2023; 43(6):1363-1371.

PMID: 37916442 PMC: 11063119. DOI: 10.1002/nau.25326.


Comparing effects of alpha-blocker management on acute urinary retention secondary to benign prostatic hyperplasia: A systematic review and network meta-analysis.

Gwon Y, Park J, Yang W, Doo S, Kim J, Kim D Prostate Int. 2023; 11(2):91-99.

PMID: 37409094 PMC: 10318332. DOI: 10.1016/j.prnil.2022.12.002.


Electronic medical records-based retrospective, longitudinal, observational study to understand the patient management of benign prostatic hyperplasia with alpha-blockers monotherapy in Indian population.

Gupta R, Trivedi S, Vaddi S, Borgohain M, Mittal R, Pandit S Urol Ann. 2023; 15(2):138-147.

PMID: 37304518 PMC: 10252785. DOI: 10.4103/ua.ua_114_21.